New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report

Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID‐19) vaccination have been reported. Herein, we report a case of a man who developed anti‐glutamic acid decarboxylase (GAD) antibody‐positive fulminant type 1 diabetes 15 weeks after COVID‐19 vaccination, atypic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takaaki, Yakou, Fumiyoshi, Saburi, Masuo, Hirose, Ai, Akaoka, Hiroaki, Hirota, Yusuke, Yunaiyama, Daisuke, Asahi, Nobuteru, Ohno, Atsushi, Matsushita, Takaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576963/
https://www.ncbi.nlm.nih.gov/pubmed/36267825
http://dx.doi.org/10.1002/ccr3.6473
_version_ 1784811648126550016
author Kobayashi, Takaaki
Yakou, Fumiyoshi
Saburi, Masuo
Hirose, Ai
Akaoka, Hiroaki
Hirota, Yusuke
Yunaiyama, Daisuke
Asahi, Nobuteru
Ohno, Atsushi
Matsushita, Takaya
author_facet Kobayashi, Takaaki
Yakou, Fumiyoshi
Saburi, Masuo
Hirose, Ai
Akaoka, Hiroaki
Hirota, Yusuke
Yunaiyama, Daisuke
Asahi, Nobuteru
Ohno, Atsushi
Matsushita, Takaya
author_sort Kobayashi, Takaaki
collection PubMed
description Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID‐19) vaccination have been reported. Herein, we report a case of a man who developed anti‐glutamic acid decarboxylase (GAD) antibody‐positive fulminant type 1 diabetes 15 weeks after COVID‐19 vaccination, atypical of the previously reported anti‐GAD antibody‐negative cases.
format Online
Article
Text
id pubmed-9576963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95769632022-10-19 New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report Kobayashi, Takaaki Yakou, Fumiyoshi Saburi, Masuo Hirose, Ai Akaoka, Hiroaki Hirota, Yusuke Yunaiyama, Daisuke Asahi, Nobuteru Ohno, Atsushi Matsushita, Takaya Clin Case Rep Case Report Adverse reactions, including the onset of diabetes, after coronavirus disease 2019 (COVID‐19) vaccination have been reported. Herein, we report a case of a man who developed anti‐glutamic acid decarboxylase (GAD) antibody‐positive fulminant type 1 diabetes 15 weeks after COVID‐19 vaccination, atypical of the previously reported anti‐GAD antibody‐negative cases. John Wiley and Sons Inc. 2022-10-17 /pmc/articles/PMC9576963/ /pubmed/36267825 http://dx.doi.org/10.1002/ccr3.6473 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Kobayashi, Takaaki
Yakou, Fumiyoshi
Saburi, Masuo
Hirose, Ai
Akaoka, Hiroaki
Hirota, Yusuke
Yunaiyama, Daisuke
Asahi, Nobuteru
Ohno, Atsushi
Matsushita, Takaya
New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
title New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
title_full New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
title_fullStr New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
title_full_unstemmed New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
title_short New‐onset atypical fulminant type 1 diabetes after COVID‐19 vaccination: A case report
title_sort new‐onset atypical fulminant type 1 diabetes after covid‐19 vaccination: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576963/
https://www.ncbi.nlm.nih.gov/pubmed/36267825
http://dx.doi.org/10.1002/ccr3.6473
work_keys_str_mv AT kobayashitakaaki newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT yakoufumiyoshi newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT saburimasuo newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT hiroseai newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT akaokahiroaki newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT hirotayusuke newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT yunaiyamadaisuke newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT asahinobuteru newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT ohnoatsushi newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport
AT matsushitatakaya newonsetatypicalfulminanttype1diabetesaftercovid19vaccinationacasereport

Ejemplares similares